Abstract
The TP53 mutation profile in chronic lymphocytic leukemia (CLL) and the correlation of TP53 mutations with allele status or associated molecular genetics are currently unknown. We performed a large mutation analysis of TP53 at four centers and characterized the pattern of TP53 mutations in CLL. We report on 268 mutations in 254 patients with CLL. Missense mutations appeared in 74% of cases compared with deletions and insertions (20%), nonsense (4%) and splice site (2%) mutations. The majority (243 of 268) of mutations were located in the DNA-binding domain. Transitions were found in 131 of 268 mutations, with only 41 occurring at methylated CpG sites (15%), suggesting that transitions at CpGs are uncommon. The codons most frequently mutated were at positions 175, 179, 248 and 273; in addition, we detected a common 2-nt deletion in the codon 209. Most mutations (199 of 259) were accompanied by deletion of the other allele (17p–). Interestingly, trisomy 12 (without 17p–) was only found in one of 60 cases with TP53 mutation (without 17p–) compared with 60 of 16 in the cohort without mutation (P=0.006). The mutational profile was not different in the cohorts with and without previous therapy, suggesting that the mechanism underlying the development of mutations may be similar, independent of treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Joerger AC, Fersht AR . Structural biology of the tumor suppressor p53. Annu Rev Biochem 2008; 77: 557–582.
Soussi T, Wiman KG . Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 2007; 12: 303–312.
Soussi T . p53 alterations in human cancer: more questions than answers. Oncogene 2007; 26: 2145–2156.
Zenz T, Kröber A, Scherer K, Habe S, Bühler A, Benner A et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008; 112: 3322–3329.
Dicker F, Herholz H, Schnittger S, Nakao A, Patten N, Wu L et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 2009; 23: 117–124.
Rossi D, Cerri M, Deambrogi C, Sozzi E, Cresta S, Rasi S et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res 2009; 15: 995–1004.
Zenz T, Häbe S, Denzel T, Mohr J, Winkler D, Bühler A et al. Detailed analysis of p53 pathway defects in fludarabine-refractory CLL: dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009; 114: 2589–2597.
Malcikova J, Smardova J, Rocnova L, Tichy B, Kuglik P, Vranova V et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival and response to DNA damage. Blood 2009; 114: 5307–5314.
Trbusek M, Malcikova J, Smardova J, Kuhrova V, Mentzlova D, Francova H et al. Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment. Leukemia 2006; 20: 1159–1161.
Zenz T, Mohr J, Edelmann J, Sarno A, Hoth P, Heuberger M et al. Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway. Leuk Lymphoma 2009; 50: 510–513.
Bromidge T, Johnson S, Howe D . Spectrum of p53 mutations in low-grade B-cell malignancies. Leukemia 2008; 22: 1071–1073.
Newcomb EW . P53 gene mutations in lymphoid diseases and their possible relevance to drug resistance. Leuk Lymphoma 1995; 17: 211–221.
Newcomb EW, el Rouby S, Thomas A . A unique spectrum of p53 mutations in B-cell chronic lymphocytic leukemia distinct from that of other lymphoid malignancies. Mol Carcinog 1995; 14: 227–232.
Prokocimer M, Unger R, Rennert HS, Rotter V, Rennert G . Pooled analysis of p53 mutations in hematological malignancies. Hum Mutat 1998; 12: 4–18.
Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P et al. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 1995; 92: 3963–3967.
Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85: 1580–1589.
Smardova J, Nemajerova A, Trbusek M, Vagunda V, Kovarik J . Rare somatic p53 mutation identified in breast cancer: a case report. Tumour Biol 2001; 22: 59–66.
Smardova J, Pavlova S, Koukalova H . Determination of optimal conditions for analysis of p53 status in leukemic cells using functional analysis of separated alleles in yeast. Pathol Oncol Res 2002; 8: 245–251.
Waridel F, Estreicher A, Bron L, Flaman JM, Fontolliet C, Monnier P et al. Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract. Oncogene 1997; 14: 163–169.
Malcikova J, Smardova J, Pekova S, Cejkova S, Kotaskova J, Tichy B et al. Identification of somatic hypermutations in the TP53 gene in B-cell chronic lymphocytic leukemia. Mol Immunol 2008; 45: 1525–1529.
Morabito F, Filangeri M, Callea I, Sculli G, Callea V, Fracchiolla NS et al. Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with in vitro sensitivity to chlorambucil and purine analogs. Haematologica 1997; 82: 16–20.
Watanabe T, Hotta T, Ichikawa A, Kinoshita T, Nagai H, Uchida T et al. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 1994; 84: 3158–3165.
Saddler C, Ouillette P, Kujawski L, Shangary S, Talpaz M, Kaminski M et al. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 2008; 111: 1584–1593.
Soussi T, Rubio-Nevado JM, Ishioka C . MUT-TP53: a versatile matrix for TP53 mutation verification and publication. Hum Mutat 2006; 27: 1151–1154.
Soussi T, Asselain B, Hamroun D, Kato S, Ishioka C, Claustres M . et al. Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection. Clin Cancer Res 2006; 12: 62–69.
Cordone I, Masi S, Mauro FR, Soddu S, Morsilli O, Valentini T et al. p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood 1998; 91: 4342–4349.
el Rouby S, Thomas A, Costin D, Rosenberg CR, Potmesil M, Silber R et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993; 82: 3452–3459.
Fenaux P, Preudhomme C, Lai JL, Quiquandon I, Jonveaux P, Vanrumbeke M et al. Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis. Leukemia 1992; 6: 246–250.
Lepelley P, Preudhomme C, Vanrumbeke M, Quesnel B, Cosson A, Fenaux P . Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis. Leukemia 1994; 8: 1342–1349.
Sturm I, Bosanquet AG, Hermann S, Guner D, Dorken B, Daniel PT . Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ 2003; 10: 477–484.
Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervit I et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84: 3148–3157.
Soussi T, Ishioka C, Claustres M, Beroud C . Locus-specific mutation databases: pitfalls and good practice based on the p53 experience. Nat Rev Cancer 2006; 6: 83–90.
Soussi T, Kato S, Levy PP, Ishioka C . Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum Mutat 2005; 25: 6–17.
Rodin SN, Rodin AS . Strand asymmetry of CpG transitions as indicator of G1 phase-dependent origin of multiple tumorigenic p53 mutations in stem cells. Proc Natl Acad Sci USA 1998; 95: 11927–11932.
Bressac B, Kew M, Wands J, Ozturk M . Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350: 429–431.
Caron de Fromentel C, Soussi T . TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer 1992; 4: 1–15.
Zenz T, Eichhorst BF, Busch R, Denzel T, Häbe S, Winkler D et al. TP53 mutation and survival in chronic lymphocytic leukaemia. JCO 2010, e-pub ahead of print 9 August 2010.
Stilgenbauer S, Zenz T, Winkler D, Buhler A, Busch R, Fingerle-Rowson G et al. Genomic aberrations, VH mutation status and outcome after fludarabine and cyclophosphamide (FC) or FC plus rituximab (FCR) in the CLL8 Trial. ASH Annu Meeting Abstr 2008; 112: 781.
Acknowledgements
The study was supported by Grant NS9858-3/2009 and NS10439-3/2009 provided by the Internal Grant Agency of the Ministry of Health of the Czech Republic and the German José Carreras Leukemia Foundation (R06/28v).
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Zenz, T., Vollmer, D., Trbusek, M. et al. TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia 24, 2072–2079 (2010). https://doi.org/10.1038/leu.2010.208
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2010.208
Keywords
This article is cited by
-
A genetic profiling guideline to support diagnosis and clinical management of lymphomas
Clinical and Translational Oncology (2023)
-
High-Risk Mantle Cell Lymphoma in the Era of Novel Agents
Current Hematologic Malignancy Reports (2021)
-
Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative
Annals of Hematology (2021)
-
Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients
Scientific Reports (2020)
-
Design and MinION testing of a nanopore targeted gene sequencing panel for chronic lymphocytic leukemia
Scientific Reports (2018)